Skip to main content
Fig. 13 | Journal of Experimental & Clinical Cancer Research

Fig. 13

From: Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Fig. 13

Heatmap of the 1% most variable methylation probes in terms of median absolute deviation (MAD). Probes methylated above mean are reported in red, below mean in blue; the color intensity indicates the distance from mean values. Samples are annotated with two color bars at the top of the heatmap (treatment class): green=with Guad , gold=without Guad. The second color bar (treatment ID) reports mouse treatment as Control (Ctrl), Guad alone or combined with one (Guad/α-CTLA-4, α-PD-1) or both immune check-point inhibitors (Guad/ICBs). Clusters defined by the Pheatmap package [37] are reported by the dendrogram on top of the heatmap

Back to article page